Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.

Most children with IBD who initiate biologics would not have been eligible to be included in the corresponding regulatory RCTs. The outcomes of ineligible patients were worse than for eligible patients. Results from RCTs should be interpreted with caution when applied to clinical practice.